Novo Nordisk, the pharmaceutical firm behind Wegovy and Ozempic, has initiated a lawsuit against rival company Eli Lilly. The legal action alleges that Eli Lilly engaged in false advertising regarding the efficacy of its competing weight-loss treatments, Mounjaro and Zepbound.
The lawsuit, filed in the United States, claims that Eli Lilly’s marketing campaigns are designed to create a false perception of superiority. Novo Nordisk asserts that its competitor purposefully compared Eli Lilly’s highest dose medications against lower-dose versions of Novo Nordisk’s products while ignoring more recent, higher-dose offerings. According to the filing, this constitutes a violation of state and federal unfair competition and advertising statutes.
John F. Kuckelman, a senior executive at Novo Nordisk, stated that patients require precise data based on the latest scientific evidence to make health decisions. He argued that small print disclaimers are insufficient to correct the misleading nature of these national campaigns. Novo Nordisk is requesting that the court force Eli Lilly to halt these advertisements and launch a corrective campaign. If the ads are not removed, the company intends to pursue a preliminary injunction to stop them.
This legal confrontation highlights the intense rivalry between the two firms as they compete for dominance in a weight-loss drug market that analysts predict could exceed $100 billion by 2030.
